ロード中...
Immune-mediated Adverse Effects of Anti-CTLA-4 Antibody Therapy in Metastatic Melanoma
Ipilimumab, an antibody that blocks cytotoxic T lymphocyte-associated antigen-4 (CTLA-4; CD152), was approved by the Food and Drug Administration (FDA) in 2011 for the treatment of unresectable stage III or IV malignant melanoma. Although the addition of this particular immunotherapy has broadened t...
保存先:
| 出版年: | Transl Res |
|---|---|
| 主要な著者: | , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2015
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4609598/ https://ncbi.nlm.nih.gov/pubmed/26118951 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.trsl.2015.06.005 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|